Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0360 Transporter Info
Gene Name SLC43A1
Transporter Name L-type amino acid transporter 3
Gene ID
8501
UniProt ID
O75387
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Chemical Compound

  DT Modulation1

 Zinc Acetate co-treated with motexafin gadolinium results in increased expression of SLC43A1 mRNA [2]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 Testosterone co-treated with Calcitriol results in increased expression of SLC43A1 mRNA [4]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 Testosterone co-treated with Calcitriol results in increased expression of SLC43A1 mRNA [4]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 Cyclosporine affects the expression of SLC43A1 mRNA [32]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation1

 NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  2,2',4,4'-tetrabromodiphenyl ether

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of SLC43A1 mRNA [25]

Regulation Mechanism

 Transcription Factor Info

  4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation3

 NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  abrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 abrine results in decreased expression of SLC43A1 mRNA [27]

Regulation Mechanism

 Transcription Factor Info

  allyl 2,4,6-tribromophenyl ether

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 allyl 2,4,6-tribromophenyl ether results in increased expression of SLC43A1 mRNA [16]

Regulation Mechanism

 Transcription Factor Info

  belinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 belinostat results in increased expression of SLC43A1 mRNA [7]

Regulation Mechanism

 Transcription Factor Info

  bisphenol A

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 bisphenol A analog results in increased expression of SLC43A1 mRNA [21]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 bisphenol A results in increased expression of SLC43A1 mRNA [30]

Regulation Mechanism

 Transcription Factor Info

  di-n-butylphosphoric acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 di-n-butylphosphoric acid affects the expression of SLC43A1 mRNA [33]

Regulation Mechanism

 Transcription Factor Info

  dorsomorphin

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation3

 NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  entinostat

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 entinostat results in increased expression of SLC43A1 mRNA [7]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC43A1 mRNA [26]

Regulation Mechanism

 Transcription Factor Info

  Isoflavones

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Isoflavones results in decreased expression of SLC43A1 mRNA [34]

Regulation Mechanism

 Transcription Factor Info

  methylmercuric chloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 methylmercuric chloride results in increased expression of SLC43A1 mRNA [13]

Regulation Mechanism

 Transcription Factor Info

  Methyl Methanesulfonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Methyl Methanesulfonate results in increased expression of SLC43A1 mRNA [35]

Regulation Mechanism

 Transcription Factor Info

  motexafin gadolinium

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 motexafin gadolinium results in increased expression of SLC43A1 mRNA [2]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 Zinc Acetate co-treated with motexafin gadolinium results in increased expression of SLC43A1 mRNA [2]

Regulation Mechanism

 Transcription Factor Info

  Niclosamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Niclosamide results in increased expression of SLC43A1 mRNA [36]

Regulation Mechanism

 Transcription Factor Info

  Okadaic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Okadaic Acid results in decreased expression of SLC43A1 mRNA [37]

Regulation Mechanism

 Transcription Factor Info

  quinocetone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 quinocetone results in decreased expression of SLC43A1 mRNA [39]

Regulation Mechanism

 Transcription Factor Info

  sodium arsenite

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 sodium arsenite results in decreased expression of SLC43A1 mRNA [23]

Regulation Mechanism

 Transcription Factor Info

  DT Modulation2

 sodium arsenite results in increased expression of SLC43A1 mRNA [40]

Regulation Mechanism

 Transcription Factor Info

  Tetrachlorodibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Tetrachlorodibenzodioxin results in decreased expression of SLC43A1 mRNA [28]

Regulation Mechanism

 Transcription Factor Info

  trichostatin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 trichostatin A results in increased expression of SLC43A1 mRNA [15]

Regulation Mechanism

 Transcription Factor Info

  tri-o-cresyl phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 tri-o-cresyl phosphate results in increased expression of SLC43A1 mRNA [41]

Regulation Mechanism

 Transcription Factor Info

  triphenyl phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 triphenyl phosphate affects the expression of SLC43A1 mRNA [33]

Regulation Mechanism

 Transcription Factor Info

  Vanadates

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Vanadates results in decreased expression of SLC43A1 mRNA [42]

Regulation Mechanism

 Transcription Factor Info

Nanoparticle

  perfluoro-n-nonanoic acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 perfluoro-n-nonanoic acid results in increased expression of SLC43A1 mRNA [38]

Regulation Mechanism

 Transcription Factor Info

Approved Drug

  Verapamil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Verapamil inhibits the transportation of L-leucine by SLC43A1 [1]

Affected Drug/Substrate

 L-leucine Modulation Type Inhibition

Cell System

 Human prostate cancer cell lines (LNCaP)

  Zinc Acetate

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Zinc Acetate increases the expression of SLC43A1 [2]

  Mifepristone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Mifepristone inhibits the expression of SLC43A1 [3]

  Calcitriol

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Calcitriol increases the expression of SLC43A1 [4]

  Testosterone

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Testosterone inhibits the expression of SLC43A1 [4]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Acetaminophen inhibits the expression of SLC43A1 [5]

  Arsenic Trioxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Arsenic Trioxide increases the expression of SLC43A1 [6]

  Cyclophosphamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Cyclophosphamide inhibits the expression of SLC43A1 [6]

  Belinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Belinostat increases the expression of SLC43A1 [7]

  Panobinostat

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Panobinostat increases the expression of SLC43A1 [7]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Cisplatin inhibits the expression of SLC43A1 [8]

  Cyclosporine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Cyclosporine increases the expression of SLC43A1 [9]

  Doxorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Doxorubicin inhibits the expression of SLC43A1 [10]

  Sunitinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Sunitinib increases the expression of SLC43A1 [11]

  Tretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Tretinoin inhibits the expression of SLC43A1 [12]

  Valproic Acid

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Valproic Acid increases the expression of SLC43A1 [13]

Drug in Phase 2 Trial

  Motexafin gadolinium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Motexafin gadolinium increases the expression of SLC43A1 [2]

  MS-275

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 MS-275 increases the expression of SLC43A1 [7]

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Bisphenol A increases the expression of SLC43A1 [21]

Drug in Phase 1 Trial

  Trichostatin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Trichostatin A increases the expression of SLC43A1 [15]

  Dihydrotestosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Dihydrotestosterone increases the expression of SLC43A1 [20]

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Sodium arsenite inhibits the expression of SLC43A1 [23]

Drug in Preclinical Test

  (+)-JQ1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 (+)-JQ1 inhibits the expression of SLC43A1 [18]

Investigative Drug

  Metribolone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Metribolone increases the expression of SLC43A1 [14]

Natural Product

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Tobacco Smoke Pollution inhibits the expression of SLC43A1 [22]

  Caffeine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Caffeine results in decreased phosphorylation of SLC43A1 protein [31]

Regulation Mechanism

 Transcription Factor Info

Environmental toxicant

  2,3-dibromopropyl-2,4,6-tribromophenyl ether

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 2,3-dibromopropyl-2,4,6-tribromophenyl ether increases the expression of SLC43A1 [16]

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Polychlorinated dibenzodioxin inhibits the expression of SLC43A1 [24]

Mycotoxins

  Aflatoxin B1

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Aflatoxin B1 inhibits the expression of SLC43A1 [19]

  DT Modulation2

 Aflatoxin B1 affects the expression of SLC43A1 protein [28]

Regulation Mechanism

 Transcription Factor Info

  ochratoxin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 ochratoxin A metabolite results in decreased expression of SLC43A1 mRNA [6]

Regulation Mechanism

 Transcription Factor Info

Acute Toxic Substance

  Ochratoxin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Ochratoxin A inhibits the expression of SLC43A1 [6]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Benzo(a)pyrene inhibits the expression of SLC43A1 [6]

  Arsenic

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 Arsenic affects the methylation of SLC43A1 gene [29]

Regulation Mechanism

 Transcription Factor Info

Health and Environmental Toxicant

  tris(1,3-dichloro-2-propyl)phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation1

 tris(1,3-dichloro-2-propyl)phosphate increases the expression of SLC43A1 [17]
References
1 Bioactive Dihydro--agarofuran Sesquiterpenoids from the Australian Rainforest Plant Maytenus bilocularis. J Nat Prod. 2016 May 27;79(5):1445-53.
2 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
3 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
4 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
5 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
6 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
7 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
8 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
9 Integrative "-Omics" Analysis in Primary Human Hepatocytes Unravels Persistent Mechanisms of Cyclosporine A-Induced Cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
10 Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
11 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
12 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
13 Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
14 Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006 Sep 29;7:246.
15 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
16 Identification of a group of brominated flame retardants as novel androgen receptor antagonists and potential neuronal and endocrine disrupters. Environ Int. 2015 Jan;74:60-70.
17 Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
18 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
19 Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
20 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
21 Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor alpha. Toxicol Appl Pharmacol. 2020 Jul 15;399:115030.
22 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
23 Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Arch Toxicol. 2021 Jul;95(7):2351-2365.
24 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
25 Cytotoxicity and gene expression profiling of two hydroxylated polybrominated diphenyl ethers in human H295R adrenocortical carcinoma cells. Toxicol Lett. 2009;185(1):23-31.
26 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
27 Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
28 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
29 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106.
30 Bisphenol A and Bisphenol S Induce Distinct Transcriptional Profiles in Differentiating Human Primary Preadipocytes. PLoS One. 2016 Sep 29;11(9):e0163318.
31 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022;449:116110.
32 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
33 Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
34 Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. J Nutr. 2007;137(4):964-72.
35 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
36 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023;83(2):181-194.
37 A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
38 Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol. 2020 Sep;94(9):3137-3155.
39 Genomic and proteomic analysis of the inhibition of synthesis and secretion of aldosterone hormone induced by quinocetone in NCI-H295R cells. Toxicology. 2016;350-352:1-14.
40 High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
41 Organophosphate ester tri-o-cresyl phosphate interacts with estrogen receptor in MCF-7 breast cancer cells promoting cancer growth. Toxicol Appl Pharmacol. 2020;395:114977.
42 Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. Metallomics. 2012 Aug;4(8):784-93.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.